<https://rdf.molmedb.upol.cz/reference/ref2999> <http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/membrane46>,
		<https://identifiers.org/molmedb/MM489447>,
		<https://identifiers.org/molmedb/MM488716>,
		<https://rdf.molmedb.upol.cz/interaction/method71>,
		<https://identifiers.org/molmedb/MM489489>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/ontology/bibo/doi> "10.1021/acs.jmedchem.6b01197"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM489448>;
	<http://purl.org/ontology/bibo/pmid> "28355078"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/bibliographicCitation> "Wada Y, Nakano S, Morimoto A, Kasahara KI, Hayashi T, Takada Y, Suzuki H, Niwa-Sakai M, Ohashi S, Mori M, Hirokawa T, Shuto S.: Discovery of Novel Indazole Derivatives as Orally Available β<sub>3</sub>-Adrenergic Receptor Agonists Lacking Off-Target-Based Cardiovascular Side Effects. J Med Chem, Volume 60 (8), 2017"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://rdf.molmedb.upol.cz/interaction/int1007395> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref2999> .
<https://rdf.molmedb.upol.cz/interaction/int1008631> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref2999> .
<https://rdf.molmedb.upol.cz/interaction/int1008787> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref2999> .
<https://rdf.molmedb.upol.cz/interaction/int1008630> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref2999> .
